The evolution of therapeutic modalities drives the adoption of single-use technologies.

Review of SUT Adoption in Biopharma Manufacturing

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

 Automating the Future of Fill/Finish

Topic

Videos

Vishal Mukund Sonje, Vaccine Manufacturing Lead, CEPI, talks about the challenges that arise in the manufacturing of vaccines in various global regions and gives a preview of his presentation at CPHI Frankfurt 2025.

CPHI Frankfurt 2025: Regulatory Challenges for Global Manufacturing of Vaccines

Pharmaceutical packaging plays an important role in sustainability efforts. Maija Pohjakallio, VP, Climate and Circular Economy, Metsä Group, explains how fiber-based packaging can help with these efforts.

CPHI Frankfurt 2025: Fiber-Based Packaging for Sustainability

Feliza Mirasol is the science editor for 

Articles

SK pharmteco boosts US peptide synthesis and purification capabilities, advancing reliable large-scale manufacturing for biopharma innovation.

SK pharmteco Strengthens Domestic API Supply Chain with New Peptide Facility

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

The new partnership will work to embed digital identification into labware, solving chain-of-identity challenges for individualized cell and gene therapies.

Say Cheese: Avantor, p-Chip Bring COI Compliance to Clinical Consumables

Webcasts

Webinar Date/Time:  Tue, Nov 18, 2025 11:00 AM EST

Scaling Spray Drying for Tomorrow’s Therapies in a Changing Global Market

Major pharmaceutical investments in the United States are expanding API, capsule, and packaging capacity, enhancing supply chain resilience and supporting domestic drug production.

US Pharma Onshoring Gains Momentum with ACG, Wilmington, Cambrex, and Sharp

At CPHI and AAPS, Ashland plans to detail the impacts of its advanced excipients: ultra-low nitrite materials curb nitrosamine risk, while high-purity sucrose stabilizes complex biologics.

Ashland Previews Fall Conference Exhibits, Including Expanded High-Purity Sugar Portfolio

Ashland Previews Fall Conference Exhibits, Including Expanded High-Purity Sugar Portfolio: Video Summary

Take this quiz to test your comprehension of one of our recent feature articles.